Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

Delcath Systems Closes Private Placement of $5.0 Million

PR Newswire July 20, 2022

Delcath Systems Announces Private Placement of $5.0 Million

PR Newswire July 18, 2022

Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting

GlobeNewswire June 6, 2022

Delcath Systems Reports First Quarter 2022 Results and Provides Business Update

GlobeNewswire May 10, 2022

Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting

GlobeNewswire May 9, 2022

Delcath Systems to Host First Quarter 2022 Results

GlobeNewswire April 28, 2022

Delcath Systems to Participate in the Canaccord Genuity Horizons in Oncology Conference

GlobeNewswire April 8, 2022

Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference

GlobeNewswire March 29, 2022

Delcath Systems Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update

GlobeNewswire March 25, 2022

Delcath Systems to Host Fourth Quarter and Full Year 2021 Results

GlobeNewswire March 15, 2022

Delcath Systems to Present at the 34th Annual Roth Conference

GlobeNewswire March 10, 2022

Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe

GlobeNewswire March 2, 2022

Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®

GlobeNewswire February 22, 2022

Delcath Systems to Present at Upcoming Virtual Investor Conferences

GlobeNewswire February 10, 2022

Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant Reported

GlobeNewswire February 7, 2022

Results of Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Melanoma Research

GlobeNewswire February 3, 2022

David Hoffman Joins Delcath Systems, Inc. as General Counsel and Corporate Secretary

GlobeNewswire January 25, 2022

Delcath Systems to Present at the H.C. Wainwright BioConnect Virtual Investor Conference on January 10, 2022

GlobeNewswire January 7, 2022

Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato(TM) in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

GlobeNewswire December 2, 2021

Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting

GlobeNewswire November 30, 2021